Document is current

Article History

Received: 3 March 2022

Accepted: 2 August 2022

First Online: 17 August 2022

Declarations

:

: <b>R.J. Boosman, M. Jebbink, S.L. Groenland, B.A.M.H. van Veggel, E.F. Smit</b> and <b>A.D.R. Huitema</b> declare they have no conflict of interest to report.<b>W.B. Veldhuis</b> is a Cofounder and minority shareholder of Quantib BV.<b>P. Moeskops</b> is an employee of Quantib BV.<b>A.J. de Langen</b> received grants from BMS, MSD, Boehringer, AstraZeneca and non-financial support from Merck Serono and Roche, outside the submitted work.<b>J.H. Beijnen</b> has received payment for expert testimony for Hoyng Tokh Monegier (paid to their institution), is a part-time employee and (in)direct stockholder of Modra Pharmaceuticals and (jointly) holds a patent on oral taxane formulations, which are clinically developed by Modra Pharmaceuticals. Modra Pharmaceuticals is a small spin-off company of the Netherlands Cancer Institute. All of these conflicts are outside of the submitted work.<b>N. Steeghs</b> provided consultation or attended advisory boards for Boehringer Ingelheim, Ellipses Pharma. N Steeghs received research grants for the institute from AB Science, Abbvie, Actuate Therapeutics, ADCtherapeutics, Amgen, Array, Ascendis Pharma, Astex, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, BridgeBio, Bristol-Myers Squibb, Cantargia, Celgene, CellCentric, Cresecendo, Cytovation, Deciphera, Eli Lilly, Exelixis, Genentech, Genmab, Gilead, GlaxoSmithKline, Incyte, InteRNA, Janssen/Johnson&Johnson, Kinate, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Novartis, Numab, Pfizer, Pierre Fabre, Regeneron, Roche, Sanofi, Seattle Genetics, Servier, Taiho, Takeda (outside the submitted work).